Rangeley Capital bets on drugs and boxes
By Suzy Kenly Waite
Tue Jun 28, 2011
The New Canaan firm has generated fat returns wagering on a fat-killing drug.
In late 2007, Chris DeMuth believed there would be a
tremendous uptick in mergers and acquisitions. To exploit the
trend, he left his job as an event-driven analyst at Mangan
& McColl Partners and launched Rangeley Capital in January
The story might have ended in misery, which stocks going every
which way and mergers falling apart in the turmoil of Fall and
Winter 2008, but Rangeley Capital survived, dropping 15% in
2008, but coming back stronger than most of its...
ISSN: 2151-1845 / CDC10004H
Take a trial today and access
- Performance news, fund launches, regulation changes and people moves
- Profiles of fund managers, investors and distributors
- Live league tables
- Investor mandates
Start your subscription today!
- Access our news and performance data online from anywhere
- Receive weekly emails with the latest news and performance data
- Free copies of the bi-annual Global Review inc. the Billion Dollar Club
- 24/7 online support
- Dedicated account manager